285 related articles for article (PubMed ID: 33840257)
1. Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): The Immunopathology of a SARS-CoV2 Infection.
Tsai SF; Lu KY; Chuang HM; Liu CA
Cell Transplant; 2021; 30():963689721993769. PubMed ID: 33840257
[TBL] [Abstract][Full Text] [Related]
2. A double edged-sword - The Complement System during SARS-CoV-2 infection.
Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
[TBL] [Abstract][Full Text] [Related]
3. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
Zhang YY; Li BR; Ning BT
Front Immunol; 2020; 11():2033. PubMed ID: 32922406
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
5. Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us.
Kumar V
Int Rev Immunol; 2021; 40(1-2):5-53. PubMed ID: 32744465
[TBL] [Abstract][Full Text] [Related]
6. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
7. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
Ansariniya H; Seifati SM; Zaker E; Zare F
Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
[TBL] [Abstract][Full Text] [Related]
9. Murine-β-coronavirus-induced neuropathogenesis sheds light on CNS pathobiology of SARS-CoV2.
Chakravarty D; Das Sarma J
J Neurovirol; 2021 Apr; 27(2):197-216. PubMed ID: 33547593
[TBL] [Abstract][Full Text] [Related]
10. The amount of cytokine-release defines different shades of Sars-Cov2 infection.
Bindoli S; Felicetti M; Sfriso P; Doria A
Exp Biol Med (Maywood); 2020 Jun; 245(11):970-976. PubMed ID: 32460624
[TBL] [Abstract][Full Text] [Related]
11. Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned.
Ryabkova VA; Churilov LP; Shoenfeld Y
Clin Immunol; 2021 Feb; 223():108652. PubMed ID: 33333256
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
13. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
[TBL] [Abstract][Full Text] [Related]
14. An enlightening role for cytokine storm in coronavirus infection.
Zhao Z; Wei Y; Tao C
Clin Immunol; 2021 Jan; 222():108615. PubMed ID: 33203513
[TBL] [Abstract][Full Text] [Related]
15. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
16. Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses.
O'Connell P; Aldhamen YA
Hum Vaccin Immunother; 2020 Dec; 16(12):2980-2991. PubMed ID: 32878546
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: Between Past and Present.
Assaf AM; Haddadin RN; Akour AA
Viral Immunol; 2021 Apr; 34(3):145-157. PubMed ID: 33017280
[TBL] [Abstract][Full Text] [Related]
18. The potential association between PARP14 and SARS-CoV-2 infection (COVID-19).
Tauber AL; Schweiker SS; Levonis SM
Future Med Chem; 2021 Mar; 13(6):587-592. PubMed ID: 33467912
[TBL] [Abstract][Full Text] [Related]
19. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
